Wave Life Sciences
Wave RNA Editing Restores Enzyme in Genetic Disorder but Fails to Impress Investors
Wave Life Sciences; RNA editing; AATD; alpha-1 antitrypsin deficiency; enzyme restoration; clinical trial; investor reaction; WVE-006
Wave Life Sciences Shares Dip After Mixed Data Update on GSK-Partnered AATD Therapy
Wave Life Sciences; GSK; AATD; RNA editing; WVE-006; clinical trial; protein levels; stock dip; biotech
Wave Life Sciences Sees Historic Stock Surge Following Breakthrough in RNA Editing Therapy
Wave Life Sciences, RNA editing, genetic condition, lung and liver complications, WVE-006, biotech, stock surge, clinical trial data
Takeda Terminates Partnership with Wave Life Sciences on Huntington’s Disease Program
Takeda, Wave Life Sciences, Huntington’s disease, WVE-003, partnership termination, biotech news
Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment
Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression
Wave Life Sciences Achieves Breakthrough in Huntington’s Disease Treatment with WVE-003, Eyes Accelerated Approval
Wave Life Sciences, Huntington’s disease, WVE-003, Phase Ib/IIa study, accelerated approval, mutant huntingtin protein, allele-selective silencing, RNA medicine